-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Laterality of Renal Cell Carcinoma Predicts Survival in Certain Patient Subgroups
Patients with right-sided renal cell carcinoma are significantly more likely to have favorable clinicopathological features than patients with left-sided disease, and they have significantly better cancer-specific survival within certain subgroups.
-
Biopsy Tract Seeding Resulting in Perirenal Tissue Involvement in RCC May Not Warrant Upstaging
Kristine M. Cornejo, MD, genitourinary pathologist at Mass General and the Mass General Cancer Center, and colleagues determined that pT1 renal cell carcinomas that have perinephric fat involvement due to biopsy tract seeding, without other upstaging variables, behave more like pT1 tumors than tumors that are staged as pT3a due to true invasion.
-
Long-term Safety Profile of Salvage Cystectomy After Trimodality Therapy Seems Acceptable
Salvage cystectomy after trimodality therapy is associated with a higher rate of late complications than primary cystectomy, according to Matthew F. Wszolek, MD, and colleagues. However, the increased risk of late complications does not influence overall survival.
-
Considerations in Selecting Patients for Trimodal Therapy for Muscle-invasive Bladder Cancer
Adam S. Feldman, MD, MPH, and colleagues review the patient-related and tumor-related factors that should most strongly influence the decision between trimodal therapy and radical cystectomy for patients with muscle-invasive bladder cancer.
Mass General Cancer Center Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Prostate Cancer Patients with Posterior Positive Surgical Margins Have Poorer Prognosis
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy -
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
Prostate Cancer and Translational Research
-
-
Jason A. Efstathiou, MD, DPhil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
